Progress in Multiple Myeloma

<乌鸦传媒 class="article_title"> Are Multiple Myeloma Patients Getting the Treatments They Need?

Some are, some aren鈥檛. Although advances in treating multiple myeloma have increased survival rates, a study from the Cleveland Clinic reports that factors such as race, insurance type, and treatment facility affect who gets recommended treatments.

<乌鸦传媒 class="article_title"> The Great Smoldering Myeloma Debate: Observe or Intervene?

A retrospective study examines the myeloma-defining events and clinical presentations leading to a multiple myeloma (MM) diagnosis in a group of patients with smoldering MM.

<乌鸦传媒 class="article_title"> Multiple Myeloma Treatment Tolerability: Ask the Patients

Is it possible that the answer to a single question asked of patients starting treatment for newly diagnosed multiple myeloma will identify those who may discontinue treatment because of adverse events?

<乌鸦传媒 class="article_title"> Myeloma Diagnostic Tool Introduced for Primary Care Settings

Myeloma is the cancer with the worst delayed diagnosis rate. The Myeloma Diagnostic Tool was created to guide primary care providers regarding when to consider and how to evaluate a patient with suspected myeloma.

<乌鸦传媒 class="article_title"> For Multiple Myeloma Patients After ASCT, Nonclinical Factors Matter, Too

Race, socioeconomic status, household composition, type of available housing and transportation. All of these factors, and more, determine how well patients with multiple myeloma do after autologous stem cell transplant.

<乌鸦传媒 class="article_title"> Multiple Myeloma Treatment in Black and White Patients: It鈥檚 Different

Multiple myeloma treatment is becoming less common during the first year after diagnosis for non-Hispanic Black patients compared with non-Hispanic White patients. A new study examines the consequences of these delays.

<乌鸦传媒 class="article_title"> In Patients with Multiple Myeloma Undergoing HCT, Can Clonal Hematopoisis Predict CVD Risk?

Clonal hematopoiesis of indeterminate potential is a possible biomarker of CVD risk in patients with multiple myeloma who are undergoing hematopoietic cell transplant.

<乌鸦传媒 class="article_title"> In Multiple Myeloma, Does Obesity Affect Outcomes?

A secondary analysis of the STaMINA (BMT CTN 0702) Trial found no significant association between waist-to-hip ratio or BMI and either progression-free survival or overall survival in patients with multiple myeloma undergoing hematopoietic cell transplant.

乌鸦传媒

Sections